Arecor Therapeutics Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development

Reuters09-25

Arecor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development

Arecor Therapeutics plc has announced a new royalty financing agreement with Ligand, securing up to $11 million in non-dilutive capital. The deal includes an upfront payment of $7 million and up to an additional $4 million, contingent upon achieving specific commercial milestones related to AT220 and AT292. Ligand will also receive warrants over 1,002,739 ordinary shares of Arecor, exercisable over ten years at a set price of 67.39 pence per share. The funding is intended to support the advancement of Arecor's ultra-concentrated, ultra-rapid acting insulin candidate AT278 and the development of a novel oral delivery platform for peptides, extending Arecor's cash runway to the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arecor Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001129736-en) on September 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2570063681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570063681","market":"us","top_or_hot":-1,"title":"Arecor Therapeutics Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arecor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arecor Therapeutics plc has announced a new royalty financing agreement with Ligand, securing up to $11 million in non-dilutive capital. The deal includes an upfront payment of $7 million and up to an additional $4 million, contingent upon achieving specific commercial milestones related to AT220 and AT292. Ligand will also receive warrants over 1,002,739 ordinary shares of Arecor, exercisable over ten years at a set price of 67.39 pence per share. The funding is intended to support the advancement of Arecor's ultra-concentrated, ultra-rapid acting insulin candidate AT278 and the development of a novel oral delivery platform for peptides, extending Arecor's cash runway to the first half of 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arecor Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001129736-en) on September 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arecor Therapeutics Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArecor Therapeutics Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-25 14:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arecor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arecor Therapeutics plc has announced a new royalty financing agreement with Ligand, securing up to $11 million in non-dilutive capital. The deal includes an upfront payment of $7 million and up to an additional $4 million, contingent upon achieving specific commercial milestones related to AT220 and AT292. Ligand will also receive warrants over 1,002,739 ordinary shares of Arecor, exercisable over ten years at a set price of 67.39 pence per share. The funding is intended to support the advancement of Arecor's ultra-concentrated, ultra-rapid acting insulin candidate AT278 and the development of a novel oral delivery platform for peptides, extending Arecor's cash runway to the first half of 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arecor Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001129736-en) on September 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL8Fplkw:1","article_id":"2570063681","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570063681","pubTimestamp":1758781855,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arecor Therapeutics plc has announced a new royalty financing agreement with Ligand, securing up to $11 million in non-dilutive capital. The deal includes an upfront payment of $7 million and up to an additional $4 million, contingent upon achieving specific commercial milestones related to AT220 and AT292. Ligand will also receive warrants over 1,002,739 ordinary shares of Arecor, exercisable over ten years at a set price of 67.39 pence per share. The funding is intended to support the advancement of Arecor's ultra-concentrated, ultra-rapid acting insulin candidate AT278 and the development of a novel oral delivery platform for peptides, extending Arecor's cash runway to the first half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","AREC.UK":"ARECOR THERAPEUTICS PLC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK5083":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股"},"translate_title":"Arecor Therapeutics与Ligand达成高达1100万美元的特许权使用费融资协议，以支持管道开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AREC.UK":0.9,"NDAQ":0.9},"content_text":"Arecor Therapeutics Secures Up to $11 Million Royalty Financing Agreement with Ligand to Support Pipeline Development\n    \n\n        Arecor Therapeutics plc has announced a new royalty financing agreement with Ligand, securing up to $11 million in non-dilutive capital. The deal includes an upfront payment of $7 million and up to an additional $4 million, contingent upon achieving specific commercial milestones related to AT220 and AT292. Ligand will also receive warrants over 1,002,739 ordinary shares of Arecor, exercisable over ten years at a set price of 67.39 pence per share. The funding is intended to support the advancement of Arecor's ultra-concentrated, ultra-rapid acting insulin candidate AT278 and the development of a novel oral delivery platform for peptides, extending Arecor's cash runway to the first half of 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arecor Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001129736-en) on September 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570063681","isCrawlerRequest":true}